opdivoOpdivo (opdivo) - Nivolumab (nivolumab) - the first and only immunotherapeutic drug of proven effectiveness in the treatment of metastatic non-small cell lung cancer (NSCLC) in clinical trials. Approved by the FDA. Is prescribed for the treatment of NSCLC is widespread, and has spread after treatment with platinum-based chemotherapy.

Clinical researches

Unprecedented results of clinical trials have shown a significant improvement in survival.

The study involved 272 adult patients with advanced NSCLC who were secondary lesions after treatment with platinum-based chemotherapy. 135 patients were assigned ti nivolumab, 137 - cytostatic drug - docetaxel.

In patients after treatment opdivo improved survival by 41% compared with chemotherapy treatment. Half of the patients are alive after immunotherapy was 9.2 months compared with 6 months with docetaxel.

Opdivo drug interacts with the body's immune system, which is designed to protect against external threats (viruses and bacteria) and internal (cancer cells). However, certain malignant cells to immune attack is avoided by sending specific signals. Immunotherapy can work through those same signals to help the immune system in the fight with cancer.

This fast-growing region called immunnoonkologiey.

The mechanism of nivolumaba

The drug comes into contact with immunity to help fight lung cancer. The immune system - the first defense against such threats. Sometimes malignant cells send a signal which prevents the onset of immunity work. Opdivo blocks this signal, helping to restore the immune response against tumor cells. However, it can affect healthy cells.

  1. Normally, the immune system helps fight against cancer. Special cells - T - cells attack a threat to the organism, such as lung cancer.
  2. Some malignant lung cancer cells send receptor signal PD-1 (programmed cell death) on T cells. This signal inactivates T cells, allowing cancer grow.
  3. Nivolumab blocks a protein PD-1 on T cells, allowing them to carry out their work.

Potential serious side effects discussed in detail here , As well as the information that you need to tell your doctor before starting therapy.

How is the treatment with the drug nivolumaba?

Put a dropper, a medicine enters intravenously over 60 minutes. It is given every two weeks. The doctor will determine the required number of procedures. Performed blood tests to check and identify side effects.

Among the adverse effects of treatment of NSCLC is most often observed nausea, fatigue, constipation, shortness of breath, coughing, loss of appetite, pain in the joints, bones and muscles.

Consultations with video online a leading Israeli experts: about the benefits of online video Consultation.